Welcome to our dedicated page for Pacira Biosciences news (Ticker: PCRX), a resource for investors and traders seeking the latest updates and insights on Pacira Biosciences stock.
Overview
Pacira BioSciences Inc (NASDAQ: PCRX) is a specialty pharmaceutical company committed to revolutionizing pain management by offering innovative non-opioid therapies and regenerative health solutions. With a core focus on providing safe and effective alternatives for pain control, the company leverages its proprietary drug delivery platforms to address acute pain in surgical and chronic conditions. Its approach combines advanced pharmaceutical formulations with novel medical devices, ensuring that clinicians have access to effective treatment options that reduce reliance on opioids.
Core Technologies and Products
At the heart of Pacira's innovation is its unique product delivery technology, which encapsulates active compounds without altering their molecular structures. This platform enables controlled, extended release of medications, ensuring long-lasting efficacy. The company has successfully commercialized several non-opioid treatments:
- EXPAREL: A long-acting local anesthetic designed to provide postsurgical pain control through sustained drug release, thereby reducing the need for opioids.
- ZILRETTA: An extended-release intra-articular injection indicated for the management of osteoarthritis knee pain, offering patients prolonged relief.
- iovera®: A handheld, drug-free device that applies controlled doses of cold therapy to targeted nerves, providing immediate and lasting pain relief.
In addition to these commercial products, Pacira is advancing its pipeline with a novel gene therapy candidate, PCRX-201. This locally administered therapy aims to treat osteoarthritis by regulating inflammatory pathways, thus addressing the root causes of pain and disability.
Market Position and Business Model
Pacira BioSciences operates at the intersection of innovative drug delivery and non-opioid pain management solutions. Its business model emphasizes:
- Commercialization of Proven Therapies: The company has established a presence in markets requiring effective postsurgical and chronic pain management solutions, evidenced by the wide adoption of its therapies in diverse clinical settings.
- Advanced R&D and Pipeline Development: By investing in robust research and development programs, along with strategic partnerships, Pacira continues to expand its portfolio and maintain competitive differentiation in the specialty pharmaceutical sector.
- Regulatory and Reimbursement Strategies: With products that have secured critical reimbursement designations, Pacira enhances market access for its non-opioid therapies across different healthcare settings. This strategic emphasis supports clinician adoption and broader patient access.
Clinical and Commercial Significance
The company's focus on non-opioid pain management comes at a time when reducing opioid dependency is an urgent priority in healthcare. By developing treatments that not only manage pain effectively but also minimize opioid consumption, Pacira is addressing a key public health challenge. Its clinically validated products have been incorporated into pain management protocols in hospitals and outpatient settings alike, offering enduring benefits for patients and healthcare providers.
Innovative Edge and Future Pipeline
Pacira’s utilization of advanced drug delivery systems, such as multivesicular liposomes and precise cryoneurolysis, underscores its commitment to innovation. These technologies not only improve therapeutic outcomes but also facilitate streamlined billing and regulatory approval processes through established coding systems. With an evolving pipeline that includes gene therapy approaches, the company is poised to expand its reach into additional therapeutic areas, addressing unmet needs in the treatment of chronic and musculoskeletal pain.
Competitive Landscape and Differentiators
In a competitive market, Pacira differentiates itself through its deep expertise in non-opioid pain management and its commitment to technological advancements. The integration of robust clinical data, strategic reimbursement initiatives, and a focus on delivering sustained therapeutic benefits positions the company as a trusted innovator among healthcare practitioners. Unlike traditional pain management solutions that rely heavily on opioids, Pacira’s products are designed to provide effective relief with reduced risk of dependency, offering a clinically superior alternative in the evolving landscape of pain management.
Conclusion
With a comprehensive portfolio that spans commercial-stage products and a promising pipeline, Pacira BioSciences Inc stands as a key player in the specialty pharmaceutical industry. Its ongoing commitment to developing non-opioid pain therapies, underpinned by advanced drug delivery technologies and rigorous clinical validation, ensures that it remains an authoritative source of innovation and expertise in pain management and regenerative health.
Pacira BioSciences (Nasdaq: PCRX) reported a 15% increase in EXPAREL net product sales, totaling $41.4 million for August 2021, up from $36.1 million in the previous year. The utilization of EXPAREL, which has treated over nine million patients, is growing despite challenges in the elective surgery market due to the pandemic. The company maintains a positive outlook, expecting annual growth in the high teens and operating margins exceeding 50%. They continue to provide monthly sales updates amid ongoing uncertainties related to COVID-19.
Pacira BioSciences, Inc. (NASDAQ: PCRX) is set to participate in the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, at 7:00 AM ET. The presentation will be virtual, and investors can access the pre-recorded audio via the company's website. Pacira is recognized for its leadership in non-opioid pain management, particularly through its long-acting local analgesic, EXPAREL®, which launched in April 2012. The company also acquired the iovera°® system in 2019 to enhance its offerings in regenerative health solutions.
Pacira BioSciences reported preliminary net product sales for July 2021, achieving $40.9 million for EXPAREL and $1.0 million for iovera°. Additionally, EXPAREL's average daily sales were 117% of July 2020 levels. This growth is attributed to increasing adoption as a non-opioid analgesic during outpatient surgeries. The company acknowledges ongoing uncertainty in the elective surgery market due to potential COVID-19 variants. Monthly unaudited sales reporting will continue until clearer market visibility is established.
PARSIPPANY, N.J., Aug. 4, 2021 - Pacira BioSciences (NASDAQ: PCRX) will present at the 2021 Wedbush PacGrow Healthcare Virtual Conference on August 10, 2021, at 10:20 AM ET. Interested parties can access the live audio via the company’s website. A replay will be available for two weeks post-event. Pacira is dedicated to non-opioid pain management and regenerative health solutions, highlighted by its long-acting analgesic, EXPAREL, launched in April 2012, and the acquisition of the iovera° system in April 2019.
Pacira BioSciences (PCRX) reported strong second quarter 2021 financial results with total revenues of $135.6 million, up from $75.5 million year-over-year. EXPAREL net sales reached $130.1 million, significantly higher than $73.0 million in Q2 2020. The company achieved a GAAP net income of $19.1 million (or $0.43 per share), a recovery from a loss in the same quarter last year. Adjusted EBITDA soared to $50.3 million. Pacira also announced FDA approval for an enhanced EXPAREL manufacturing process and a distribution agreement with Eurofarma for Latin America, indicating positive growth prospects.
Pacira BioSciences has received FDA approval for an enhanced manufacturing process for its product EXPAREL (bupivacaine liposome injectable suspension), allowing it to double production capacity at a new 200-liter facility in Swindon, England. This move is anticipated to enhance gross margins and extend market exclusivity to January 2041 with the issuance of a new patent. The company aims to commence commercial sales of EXPAREL produced in this facility by the end of the year.
Pacira BioSciences (Nasdaq: PCRX) reported significant findings on the iovera° system from a study focused on total knee arthroplasty (TKA). The addition of preoperative iovera° treatment to a multimodal pain management protocol led to a remarkable 51% reduction in daily opioid consumption and notably decreased pain levels and hospital stay lengths. Analysis of 267 patients showed less than 17% had a hospital stay of two or more days compared to 99% in the control group. These outcomes highlight iovera°'s efficacy in enhancing post-surgical recovery.
Pacira BioSciences, Inc. (NASDAQ:PCRX) will announce its second quarter financial results on August 3, 2021, before U.S. market opening. Following the earnings release, a live conference call will occur at 8:30 a.m. ET. Participants can join the call by dialing 1-877-845-0779 (domestic) or 1-720-545-0035 (international), using passcode 9991311. A replay will be available for one week post-call. Pacira is known for its commitment to non-opioid pain management, with flagship product EXPAREL® launched in 2012, and acquisition of iovera°® system in 2019.
Pacira BioSciences (Nasdaq: PCRX) announced preliminary unaudited net revenue of $135.6 million for Q2 2021, primarily driven by EXPAREL sales of $130.1 million. Average daily sales of EXPAREL surged to 178% of last year for Q2 and to 120% for June. Despite ongoing challenges due to the COVID-19 pandemic impacting elective surgeries, the company remains optimistic about future growth as conditions normalize. The report also highlights increased interest in iovera° and the company's commitment to non-opioid pain management solutions.
Pacira BioSciences, Inc. (Nasdaq: PCRX) has entered a distribution agreement with Eurofarma Laboratories S.A. for the commercialization of EXPAREL® in 19 Latin American countries, including Brazil and Mexico. This partnership aims to enhance Pacira's presence in a rapidly growing market, allowing Eurofarma to leverage its extensive experience in introducing innovative products. Pacira will earn royalties and milestone payments based on Eurofarma's success in this region, reinforcing its commitment to providing non-opioid pain management solutions.
FAQ
What is the current stock price of Pacira Biosciences (PCRX)?
What is the market cap of Pacira Biosciences (PCRX)?
What is the core focus of Pacira BioSciences Inc?
How does Pacira differentiate its products in the market?
What are the key commercial-stage products offered by Pacira?
What technology underpins Pacira's drug delivery system?
How does Pacira address the issue of opioid dependency?
What is PCRX-201 and what potential does it hold?
Which healthcare settings benefit from Pacira's therapies?
What role do reimbursement strategies play in Pacira's business model?
How does Pacira support clinical decision-making and patient care?
